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work-related activities consisting of nurse, pharmacist, and/or patient medication 
dispensing, preparation, administration and/or storage. Projects consisted of time and 
cost differences related to 1) three proton pump inhibitor dosage forms and seven 
administration methods, and 2) seven recombinant human growth hormone adminis-
tration methods/devices. Performance-based time data were then used to determine 
personnel/patient opportunity time and supply costs associated with different forms 
of medications and delivery devices. Simulations were developed and used to hold 
independent variables constant so only observed differences between medications and/
or device types could be assessed. Statistical and micro-economic cost analyses were 
conducted speciﬁc to each type of medication and/or device. RESULTS: Processes and 
results show two detailed examples as case studies of how simulation-based research 
may be used to assess health care processes at the micro level. The advantages of isolat-
ing processes of interest from the day-to-day complexity of patient care are demon-
strated. Simulations may also represent an efﬁcient assessment alternative of health 
care processes at the micro level with potential for projection to the macro level as 
compared to live, direct observation, cost-intensive, patient-centered care practice 
evaluations. CONCLUSIONS: Simulation-based time-and-motion and activity-based 
cost analyses allowed detailed micro-level time, workload, and supply evaluations that 
may be projected to the macro level. Professional schools’ simulation laboratories offer 
appropriate settings for such studies.
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OBJECTIVES: Demonstrate a technique to characterize the economic burden of illness 
over time, correcting for censoring bias and controlling for difference in baseline 
characteristics between comparison groups. A sample of patients with diagnosis of 
disease A in 2004–2008 were extracted from MarketScan® databases and followed 
to death, disenrollment, or December 31, 2008 (cases). The ﬁrst diagnosis date was 
the index date. Enrollees without disease A were extracted as controls. Their index 
dates were assigned based on the distribution of index dates of cases. METHODS: 
First, Kaplan-Meier estimates for the probability of remaining in the data were calcu-
lated by month and disease status. Failure event was death or disenrollment. Censoring 
event was termination of MarketScan contract or end of study period. Next, total 
health care costs were estimated using generalized linear models (GLM) on the sub-
sample of survivors/enrollees in each month, controlling for disease status, patient 
demographic and clinical characteristics. Adjusted costs were calculated by month and 
disease status using the regression estimates and average characteristics. Estimated 
total costs during the whole follow-up period were the sum of probability of remaining 
in the data multiplied by regression-adjusted costs in each month. RESULTS: At the 
end of year 1, 40.5% of cases deceased or disenrolled from insurance compared to 
13.6% of controls (p < 0.001); at the end of year 4 these ﬁgures were 76.4% and 
30.5%, respectively (p < 0.001). GLM results indicated signiﬁcantly higher cost among 
the group with disease A in each month during follow-up. The adjusted costs based 
on average characteristics was $86,592 for cases vs. $6,178 for controls in the ﬁrst 
year and $151,077 vs. $21,890 in the ﬁrst 4 years. CONCLUSIONS: In studies with 
variable-length follow-up, an estimator combining the survivor probability and regres-
sion-adjusted cost is more robust to censoring bias, and better depicts the economic 
burden of illness over time.
CONCEPTUAL PAPERS & RESEARCH ON METHODS – Databases & 
Management Methods
PMC8
THE EFFECT OF LENGTH OF OBSERVATION AND CLAIMS DATA TYPE 
ON ESTIMATES OF COMORBIDITIES AMONG MEDICAID BENEFICIARIES
Banahan III BF, Pace PF
University of Mississippi, Oxford, MS, USA
OBJECTIVES: Researchers frequently use claims data to create comorbidity measures. 
The objective of this project was to examine how the number of months of observation 
data and the type of claims data can affect identiﬁcation of comorbidities. METHODS: 
Inpatient (IP) and outpatient (OT) claims data were used to identify comorbidities for 
beneﬁciaries enrolled in a state Medicaid program. Beneﬁciaries were included if they 
were enrolled for a continuous 24-month period between January 2002 and December 
2004. Data were used to identify the ﬁrst month in which an ICD-9 code appeared 
for each of the 17 comorbidities included in the Charlson Comorbidity Index. The 
D’Hoore scoring system was used to identify ICD-9 codes associated with each 
comorbidity. Results from the IP and OT claims were combined to create overall 
comorbidity measures. RESULTS: The study included a total of 618,337 unique 
patients. The OT claims could identify almost all comorbidities (low of 88.0% for 
myocardial infarctions, high of 99.5% for diabetes). IP claims were much less likely 
to identify comorbidities (low of 11.5% for connective tissue disease, high of 45.7% 
for myocardial infarction). At 12 months, less than half of the beneﬁciaries with 
comorbid events during the 24-month period had been identiﬁed for dementia 
(43.9%), cerobrovascular disease (45.6%), peripheral vascular disease (45.6%), and 
myocardial infarction (48.4%). In contrast, 78.1% of patients with diabetes events 
and 69.0% of patients with chronic pulmonary disease events had been identiﬁed at 
12 months. CONCLUSIONS: The percentage of patients ascribed comorbidities will 
vary signiﬁcantly depending on the number of observation months. Obviously, the 
incidence rate for new events/diagnoses contributes to the increase over time. However, 
researchers must be careful since some comorbidities may not be associated with 
frequent enough physician ofﬁce visits to accurately detect existing comorbidities when 
the number of observation months is short.
PMC9
DATA SCAFFOLDING: A PRAGMATIC APPROACH TO STRUCTURING A 
LITERATURE REVIEW SPREADSHEET TO MAXIMIZE INFORMATION, 
FACILITATE REVIEW AND SUPPORT ANALYSIS
Ogden K1, Hansen R1, Rattana S2, Neil N1
1ICON Clinical Research, Lifecycle Sciences Group, San Francisco, CA, USA, 2ICON Clinical 
Research, Lifecycle Sciences Group, Chicago, IL, USA
OBJECTIVES: Clinical literature reviews, especially systematic reviews, require the 
management and evaluation of large amounts of bibliographic data. Although the 
methodology for performing reviews is well documented, few sources share practical 
guidance on how to electronically manage citation data in order to efﬁciently inven-
tory, organize, and assess published material. Spreadsheet tools (e.g., Excel®) give 
researchers unparalleled freedom to manipulate a large volume of information culled 
from source databases (e.g., MEDLINE®); however, many researchers lack a blueprint 
for structuring their data to facilitate review. METHODS: We describe a process of 
erecting “data scaffolding” that is critical to transforming a literature review spread-
sheet into an agile, manipulable source of information that can triage, sort, and report 
on materials retrieved for review. RESULTS: Using a sample of literature data pulled 
from PubMed®, we describe several ideas for adding key structural components to a 
spreadsheet of citations that bring ﬂexibility and functionality to the processes of 
article review and analysis. In doing so, we also describe the hows and whys of 
spreadsheet design to facilitate literature review, such as the importance of the spread-
sheet layout; the addition of ﬂag ﬁelds to use medical subject headings or key words 
to easily sort, organize, identify/retrieve, navigate, and summarize citations; and ways 
of leveraging built-in spreadsheet features such as autoﬁlters, freeze-panes, and sub-
totals that can greatly facilitate the inventory and management of large volumes of 
citation data to support literature reviews. CONCLUSIONS: In an era of increasing 
volumes of published literature and the proliferation of rigorous, formalized, system-
atic and non-systematic reviews, researchers must adapt to growing demands. Existing 
spreadsheet tools can be leveraged to effectively meet these demands, in ways that not 
only provide for greater efﬁciency but in ways that may result in enhanced research 
capabilities.
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OBJECTIVES: Large epidemiology studies using population databases are in high 
demand in the current health care environment. Simultaneously, the number of health 
care databases available for research has risen considerably. Increasingly complex 
research questions require population researchers to be more aware of the availability 
and details of databases worldwide. To address this growing need, a web-based direc-
tory with detailed proﬁles of population research databases was developed. 
METHODS: B.R.I.D.G.E. TO DATASM (Beneﬁt-Risk Information for Drug Evalua-
tions) is an advanced version of the original R.A.D.A.R. (Risk Assessment of Drugs 
Analysis & Response) books (1990s; 200+ database proﬁles), and the subsequent 
BRIDGE On-Line version (1999–2003). Over a 20-month period, we convened an 
advisory board, re-branded the website, and updated content. A web development 
ﬁrm built the infrastructure of bridgetodata.org. Content was developed by assessing 
existing database proﬁles and performing extensive literature reviews. A database 
proﬁle template was created with 75 common ﬁelds covering the following categories: 
population type, demographics, physician, drug, diagnosis, procedure, economic, vali-
dation, linkage, and administrative data. We received advisory board feedback at 
multiple stages, and database managers were contacted for listing authorization and 
content approval. A quality assurance process involved systematic review of each 
proﬁle by the primary editor, DGI staff, and database managers. RESULTS: The site 
was launched in November 2009 with 50 database proﬁles from USA, Europe, and 
Asia. It features a web interface designed to perform database searches by ﬁeld type 
and to allow side-by-side comparison of multiple databases. Limitations included a 
short timeline and budgetary constraints. CONCLUSIONS: Development of a web-
based directory of population research database proﬁles will enable the identiﬁcation 
of appropriate databases for pharmacoepidemiologic, economic, and health services 
research. Other applications may include serving as an educational tool and as a model 
for developing new health care databases.
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OBJECTIVES: Due to the heterogeneous health care environment in Austria, data 
about procedures performed in outpatient clinics, ambulatories and in the outpatient 
sector have not been collected in a standardized language. However, this data is crucial 
for planning processes and health services provision. Therefore, the Ministry of Health 
in collaboration with the Austrian Social Security and 3 of 9 Federal States initiated 
